

REMARKS


Applicants acknowledge the withdrawal of previous rejections and address the new rejections herein.

Claim 18 defines a method for treating a hyper-proliferative disorder in a mammal by administering a compound of claim 1. Page 9, lines 14-15, of the specification indicates that the invention provides methods of treating cancer and other hyperproliferative disorders. While significantly more detail is provided with respect to the treatment of cancers, Applicants do not exclude the treatment of other hyperproliferative disorders such as inflammation with the compounds of this invention. No evidence has been presented to demonstrate the compounds of claim 1 would not be effective against other hyperproliferative disorders.

Claim 22 has been amended to define a method of treating osteoporosis and inflammation using a compound of claim 1. The compounds of this invention are shown to inhibit p38 kinase and raf kinase on pages 97 -100 of the specification. Compounds which inhibit p38 kinase are known to be effective in treating inflammation and osteoporosis, (See U.S. Patent No. 6,344,476) No evidence has been presented that these compounds are ineffective against such diseases and no evidence has been presented that the activity shown is inadequate to demonstrate the utility claimed. Therefore, applicants submit there is no basis for the rejection under 35 U.S.C. § 112, first paragraph ,and this rejection should be withdrawn.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Richard J. Traverso (Reg. No. 30,595)  
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER 15P4

Date: July 22, 2003